Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Shares of prostate cancer drugmaker Medivation (NASDAQ: MDVN ) closed down 6% after reporting fourth-quarter earnings, despite handily beating expectations. Sales of its flagship product Xtandi racked up $57 million in its first full quarter. Its conference call was full of questions regarding the launch, as well as discussion over a controversial research report. Watch as health-care analyst David Williamson takes you through the day's events.
Resurgence, or dead cat bounce?
Shares of Medivation's competitor Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy, and a year of free analyst updates, by clicking here now.